Nasal Vaccines Market Anticipated to Reach US$ 742.6 Million, Globally, by 2030 at 8.6% CAGR: Coherent Market Insights (CMI)
July 25, 2023 05:06 ET
|
CMI
Burlingame, July 25, 2023 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, “Nasal Vaccines Market, By Vaccine type (Live attenuated vaccines, Inactivated vaccines, Subunit,...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
November 30, 2022 15:01 ET
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
POP Biotechnologies' SNAP Vaccine Platform Enters Large-Scale Phase III Clinical Trials for COVID-19
September 20, 2022 21:31 ET
|
POP Biotechnologies, Inc.
BUFFALO, N.Y., Sept. 20, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of...
PCI Biotech fourth quarter and preliminary full year 2020 results
February 24, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 24 February 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q4 and preliminary full year 2020 results. Please find enclosed the...
PCI Biotech: US patent granted for the vaccine technology (fimaVacc) in combination with cytokines
January 21, 2020 02:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 21 January 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US...